Comparative Pharmacology
Head-to-head clinical analysis: GYNAZOLE 1 versus POSFREA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNAZOLE 1 versus POSFREA.
GYNAZOLE-1 vs POSFREA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butoconazole nitrate, an imidazole antifungal agent, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing fungal cell membrane permeability.
POSFREA is a carbapenem-class antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
One 100 mg vaginal ovule inserted intravaginally as a single dose.
IV 4 mg/kg once daily; infused over 90 minutes.
None Documented
None Documented
Terminal elimination half-life is approximately 6-7 days after intravaginal administration, reflecting slow absorption from the vaginal mucosa and prolonged retention in tissues.
12 hours (range 10-14) in healthy adults; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Primarily as unchanged drug in feces via biliary elimination; <1% excreted renally as metabolites.
Renal (95%) as unchanged drug; biliary/fecal (5%).
Category C
Category C
Azole Antifungal
Azole Antifungal